Aktiesnakken — November 2010
-
det er iøvrigt første gang at vi hører zalutumumab koster 100 mill om året. Ok så ved vi det
-
Kan det være deres outlook Tdae?
-
og nu kan vi så også konstatere at de regner med 500 mill i udgifter for 2011!
-
utroligt man skal læse det i en artikel. ØV!
-
men så ved vi da det!
-
så 400 mill i r&d 100 mill i administration og så leder han efter at hakke 100 mill yderligere af i 2011
-
hvorfor bruge penge på adm?
-
de 100 mio kan jeg let finde...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind